Tamiz A P, Whittemore E R, Zhou Z L, Huang J C, Drewe J A, Chen J C, Cai S X, Weber E, Woodward R M, Keana J F
Department of Chemistry, University of Oregon, Eugene, Oregon 97403, USA.
J Med Chem. 1998 Aug 27;41(18):3499-506. doi: 10.1021/jm980235+.
A series of bis(phenylalkyl)amines, structural analogues of ifenprodil and nylidrin, were synthesized and tested for antagonism of N-methyl-D-aspartate (NMDA) receptors. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The bis(phenylalkyl)amines were selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, the most potent of these, N-[2-(4-hydroxyphenyl)ethyl]-5-phenylpentylamine hydrochloride (20), has an IC50 value of 8 nM and >1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. The structure-activity relationship of the bis(phenylalkyl)amine series indicates that the piperidine ring and alkyl chain substitutions common to NR2B-selective antagonists such as ifenprodil, CP 101,606, and Ro 25-6981 are not necessary to generate potent and selective ligands. The primary determinants of potency are the phenolic OH group, acting as a hydrogen bond donor, the distance between the two rings, and an electrostatic interaction between the receptor and the basic nitrogen atom. This study provides a framework for designing structurally novel NR2B-selective antagonists which may be useful for treatment of a variety of neurological disorders.
合成了一系列作为艾芬地尔和尼立替林结构类似物的双(苯基烷基)胺,并对其进行了 N-甲基-D-天冬氨酸(NMDA)受体拮抗作用测试。通过在表达克隆大鼠 NMDA 受体亚基三种二元组合的非洲爪蟾卵母细胞中进行电记录来测定效力和亚基选择性:NR1A 与 NR2A、NR2B 或 NR2C 组合表达。双(苯基烷基)胺是 NR1A/2B 受体的选择性拮抗剂。在稳态条件下测定,其中最有效的 N-[2-(4-羟基苯基)乙基]-5-苯基戊胺盐酸盐(20)的 IC50 值为 8 nM,相对于 NR1A/2A 和 NR1A/2C 受体具有大于 1000 倍的选择性。双(苯基烷基)胺系列的构效关系表明,对于产生强效和选择性配体而言,艾芬地尔、CP 101,606 和 Ro 25-6981 等 NR2B 选择性拮抗剂共有的哌啶环和烷基链取代并非必需。效力的主要决定因素是作为氢键供体的酚羟基、两个环之间的距离以及受体与碱性氮原子之间的静电相互作用。本研究为设计结构新颖的 NR2B 选择性拮抗剂提供了框架,这些拮抗剂可能对治疗多种神经疾病有用。